Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006247 · ClinicalTrials.gov registry record · Phase 1
SU5416 in Treating Children With Recurrent or Progressive Brain Tumors
A Phase 1 study, sponsored by Pediatric Brain Tumor Consortium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00006247 is a Phase 1 study that was terminated before completion, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 33 participants.
The verdict
NCT00006247, a Phase 1 study, was terminated before completion, sponsored by Pediatric Brain Tumor Consortium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
RATIONALE: SU5416 may stop the growth of brain cancer cells by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the safety of delivering SU5416 in children who have recurrent or progressive brain tumors.
Interventions
- DRUG semaxanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2000-08 |
| Est. Completion | 2006-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006247
The ClinicalTrials.gov registry entry for NCT00006247 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which semaxanib is the first listed.
NCT00006247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006247 about?
NCT00006247 is a clinical study titled "SU5416 in Treating Children With Recurrent or Progressive Brain Tumors". RATIONALE: SU5416 may stop the growth of brain cancer cells by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the safety of delivering SU5416 in children who have recurrent or progressive brain tumors.
What is the current status of trial NCT00006247?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2000-08. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00006247?
The interventions under investigation include: semaxanib (DRUG).
Who is sponsoring clinical trial NCT00006247?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.